November 7, 2025PublicationRedTailSITC Poster – In Situ Tumor Delivery of IL-15 Superagonist via RedTail Gene Therapy Achieves Durable Tumor Clearance
December 13, 2022PublicationSuperNovaDevelopment of Allogeneic Stem Cell-Based Platform for Delivery and Potentiation of Oncolytic VirotherapyNational Center for Biotechnology Information
August 22, 2021PublicationNeuroNovaNeural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trialLancet Oncology
May 25, 2020PublicationSuperNovaEnhancement of the therapeutic effects of oncolytic vaccinia virus by using autologous and allogeneic cell-based delivery platforms.Journal of Clinical Oncology
May 18, 2020PublicationNeuroNovaRationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patientsThe Journal of Translational Medicine
February 4, 2020PublicationSuperNovaA cell-based platform to potentiate oncolytic virus: Potential approach for cancer therapies.Journal of Clinical Oncology
August 19, 2019PublicationSuperNovaFirst-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cellsThe Journal of Translational Medicine
August 19, 2019PublicationNeuroNovaFirst-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cellsThe Journal of Translational Medicine
March 27, 2019PublicationSuperNovaDelivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriersThe Journal of Translational Medicine
